Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boston ScientificXSWX:BSX -1.21%74 EV-to-EBITDA is 13.90 as of Jul. 19, 2026, which is 54% below its 10-year median of 29.91. GuruFocus rates XSWX:BSX with a GF Score™ of 74/100 and a GF Value™ of CHF85.51. The stock has 1 warning sign investors should review. Among 510 Medical Devices & Instruments companies, Boston Scientific ranks better than 52.35% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Boston Scientific's enterprise value is CHF60,904 Mil.
Boston Scientific's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was CHF4,383 Mil. Therefore, Boston Scientific's EV-to-EBITDA for today is 13.90.
The historical rank and industry rank for Boston Scientific's EV-to-EBITDA or its related term are showing as below:
XSWX:BSX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -368.41 Med: 29.91 Max: 72.29
Current: 13.7
During the past 13 years, the highest EV-to-EBITDA of Boston Scientific was 72.29. The lowest was -368.41. And the median was 29.91.
XSWX:BSX's EV-to-EBITDA is ranked better than 52.35% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.155
vs XSWX:BSX: 13.70
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Boston Scientific (XSWX:BSX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Boston Scientific's PE Ratio (TTM) for today is calculated as:
Boston Scientific's share price for today is CHF35.59.
Boston Scientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1.905.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Boston Scientific's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSX vs EW, GEHC, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Boston Scientific's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boston Scientific EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Boston Scientific's EV-to-EBITDA falls into.
Boston Scientific's current Enterprise Value is CHF60,904 Mil.
Boston Scientific's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF4,383 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boston Scientific (XSWX:BSX) has a EV-to-EBITDA of 13.90 as of Jul. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Boston Scientific. This is 54% below median its historical median of 29.91. According to the industry distribution chart, Boston Scientific ranks #243 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 47.6%.
Is Boston Scientific's EV-to-EBITDA too high?
Boston Scientific's current EV-to-EBITDA of 13.90 is 54% below median its 10-year median of 29.91. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.16. Boston Scientific's value of 13.90 is 1.8% below this industry median. Based on the distribution chart, Boston Scientific ranks #243 out of 510 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Boston Scientific has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's EV-to-EBITDA compare to EW and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Boston Scientific ranks #243 out of 510 companies for EV-to-EBITDA. This puts Boston Scientific in the upper half of its industry. The industry median EV-to-EBITDA is 14.16. Boston Scientific's value of 13.90 is 1.8% below this benchmark. While the company's 10-year median is 29.91 vs. the industry median of 14.16, Boston Scientific has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.16, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boston Scientific's current EV-to-EBITDA of 13.90 is 1.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Boston Scientific. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boston Scientific's current EV-to-EBITDA is 13.90, which is 54% below median its own 10-year median of 29.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Boston Scientific (XSWX:BSX) has a current EV-to-EBITDA of 13.90. The stock's GF Value™ is CHF85.51, compared to a current price of CHF35.59 — trading 58.4% below its estimated fair value. The current EV-to-EBITDA is 13.90, which is 54% below median its 10-year median of 29.91 and 1.8% below the Medical Devices & Instruments industry median of 14.16. Boston Scientific's overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Boston Scientific (XSWX:BSX), the current EV-to-EBITDA is 13.90 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boston Scientific (XSWX:BSX) Overvalued in 2026?
Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued.
The current stock price of CHF35.59 is trading 58.4% below its estimated GF Value™ of CHF85.51.
Key valuation signals for XSWX:BSX:
EV-to-EBITDA: 13.90 (54% below median its 10-year median of 29.91)
GF Value™: CHF85.51 vs. price of CHF35.59 (58.4% below fair value)
Industry Position: 1.8% below the Medical Devices & Instruments median (#243 of 510)
No single metric tells the full story. See the XSWX:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
74GF Score
Get the complete analysis for XSWX:BSX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSX has been successfully added to your 
